INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2009

Higher intake of the soy isoflavone daidzein was linked to reduced breast cancer recurrence in postmenopausal women taking tamoxifen.

Researchers prospectively followed 1,954 female breast cancer survivors for 6.31 years, ascertaining 282 recurrences, to evaluate soy isoflavone intake assessed via food frequency questionnaires an average of 23 months post-diagnosis. Suggestive trends for reduced recurrence risk were seen with increasing quintiles of daidzein and glycetin intake among postmenopausal women (P for trend = 0.08 and 0.06, respectively) and tamoxifen users (P for trend = 0.10 and 0.05, respectively). Among postmenopausal women treated with tamoxifen, those in the highest versus lowest daidzein intake (>1,453 vs. <7.7 microg/day) had a reduced risk of breast cancer recurrence (HR 0.48; 95% CI, 0.21-0.79, P = 0.008).

Shows an association, not proof of cause and effect.

Study type
Prospective cohort study
Who was studied
1,954 female breast cancer survivors diagnosed during 1997-2000
What was measured
Risk of breast cancer recurrence

THE PAPER

Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study.

Guha N, Kwan ML, Quesenberry CP, Weltzien EK, Castillo AL, Caan BJ. Breast Cancer Res Treat, 2009.

PubMed 19221874 ↗DOI 10.1007/s10549-009-0321-5 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.